Abstract
Identifying key molecular attributes can help in the risk-adapted treatment of Hodgkin lymphoma and chronic lymphocytic leukemia. At JADPRO Live, presenters reviewed best practices for managing patients with the rapidly expanding armamentarium of treatments for these patients.
